Search clinical trials for: Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)

Total 128 results

NeoTX Therapeutics Ltd.
AstraZeneca

Active, not recruiting

Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumors

Melanoma | Renal Cell Carcinoma | Hepatocellular Carcinoma | Pancreatic Adenocarcinoma | Ovarian Cancer | NSCLC | Prostate Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Endometrial Cancer | Colorectal Cancer Metastatic | Head and Neck Squamous Cell Carcinoma | Urothelial Cancer | Cervical Squamous... and other conditions

Israel
Active Biotech AB

Completed

ABR-217620 in Patients With Advanced Non-Small Cell Lung Cancer, Renal Clear Cell Carcinoma or Pancreatic Cancer

Renal Cell Carcinoma | Pancreatic Cancer | Non-Small-Cell Lung Carcinoma

United States, Norway, United Kingdom
Active Biotech AB

Completed

ABR-217620/Naptumomab Estafenatox With Interferon-alpha (IFN-alpha) Compared to IFN-alpha Alone in Patients With Advanced Renal Cell Carcinoma

Renal Cell Carcinoma

Romania, Russian Federation, United Kingdom, Ukraine, Bulgaria
NeoTX Therapeutics Ltd.
Translational Drug Development

Completed

Naptumomab Estafenatox (NAP) in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC (NT-NAP-102-1)

Non-small Cell Lung Cancer

United States
Active Biotech AB

Completed

ABR-217620 in Combination With Docetaxel in Patients With Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

United States, Denmark, Russian Federation
Rush University Medical Center
AstraZeneca

Recruiting

Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC (ESR1814205)

Stage III Non-small-cell Lung Cancer

United States
Sheba Medical Center
Rambam Health Care Campus; AstraZeneca; Tel-Aviv Sourasky Medical Center

Recruiting

Concomitant Radiotherapy, Tremelimumab & Durvalumab for Advanced NSCLC Patients Progressing on First-line Immunotherapy (CORAL-Lung)

Metastatic or Locally Advanced NSCLC

Israel
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca; Brooklyn ImmunoTherapeutics, LLC

Active, not recruiting

IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell Carcinoma

Squamous Cell Carcinoma of the Head and Neck | Oropharynx Squamous Cell Carcinoma | Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma | Metastatic Squamous Cell Carcinoma | Hypopharynx Squamous Cell Carcinoma | Paranasal Sinus Squamous Cell Carcinoma | Larynx Squamous Cell Carcinoma

United States
Catherine Shu

Withdrawn

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Nonsmall Cell Lung Cancer

United States
The Methodist Hospital Research Institute
AstraZeneca

Recruiting

Durvalumab With Trastuzumab and Pertuzumab in HER2-Enriched Breast Cancer (DTP)

Breast Cancer

United States
AstraZeneca

Active, not recruiting

Durvalumab and Tremelimumab for Pediatric Malignancies

Pediatric Cancer | Hematological Malignancies | Solid Tumor Pediatric

Spain, Italy, United States, United Kingdom, France, Netherlands, Germany
AstraZeneca

Recruiting

Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin (VOLGA)

Muscle Invasive Bladder Cancer

Netherlands, United Kingdom, Korea, Republic of, Canada, Germany, Italy, Poland, Spain, Turkey, Vietnam, Argentina, Japan, France, Brazil, Taiwan, United States, Israel, Austria, Chile, Colombia, Greece, Hong Kong, Mexico, Portugal, Russian... and more
Stanford University
AstraZeneca

Recruiting

Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)

Non-small Cell Lung Cancer Stage III | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Non-small Cell Lung Cancer Stage II

United States
Jiping Wang, MD, PhD
AstraZeneca; Sirtex Medical

Recruiting

SIRT With Tremelimumab and Durvalumab for Resectable HCC

Hepatocellular Carcinoma | Hepatocellular Cancer | Resectable Hepatocellular Carcinoma

United States
Baylor College of Medicine

Completed

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

Mesothelioma

United States
Dana-Farber Cancer Institute
AstraZeneca

Terminated

Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer

Recurrent Ovarian Carcinoma | Recurrent Cervical Carcinoma | Recurrent Endometrial Cancer | Metastatic Endometrial Cancer | Metastatic Cervical Cancer | Recurrent Vaginal Cancer | Recurrent Vulvar Cancer | Metastatic Ovarian Cancer | Recurrent Gynecological Cancer | Metastatic Vaginal Cancer | Metastatic...

United States
AstraZeneca

Completed

An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer

Prostate Cancer | Metastatic Castration-Resistant Prostate Cancer (mCRPC)

United States
Washington University School of Medicine
MedImmune LLC

Withdrawn

PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma (PIVOT-RCC)

Renal Cell Carcinoma
Joachim Aerts, MD PhD
AIM ImmunoTech Inc.; AstraZeneca BV

Recruiting

Combining Anti-PD-L1 Immune Checkpoint Inhibitor Durvalumab With TLR-3 Agonist Rintatolimod in Patients With Metastatic Pancreatic Ductal Adenocarcinoma for Therapy Efficacy (DURIPANC)

Metastatic Pancreatic Cancer

Netherlands
Seoul National University Hospital
AstraZeneca

Active, not recruiting

Window of Opportunity Trial of Neoadjuvant Olaparib and Durvalumab for Triple Negative or Low ER+ Breast Cancer

Breast Neoplasms

Korea, Republic of
Celgene

Completed

Safety and Efficacy Study of CC-486 in Subjects With Myelodysplastic Syndromes

Myelodysplastic Syndromes

United States, United Kingdom, Australia, Poland, Spain, Belgium, Italy, Germany, France, Canada
Baki Topal
AstraZeneca

Active, not recruiting

Progression-free Survival After MWA Plus Durvalumab and Tremelimumab for Unresectable Locally Advanced Pancreatic Cancer (MIMIPAC)

Pancreatic Cancer Non-resectable

Belgium
University of Cologne
AstraZeneca

Not yet recruiting

Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (GUIDANCE)

Small Cell Lung Carcinoma
University of British Columbia
AstraZeneca; Ozmosis Research Inc.

Recruiting

SCION: SABR and Checkpoint Inhibition Of NSCLC (SCION)

Carcinoma, Non-Small-Cell Lung | Lung Cancer | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer Stage I | Lung Cancer Stage I | Lung Adenocarcinoma, Stage I | Lung Squamous Cell Carcinoma Stage I

Canada
AstraZeneca

Terminated

A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer (SCope-D1)

Small Cell Lung Cancer | Non-Small Cell Lung Cancer

United States, Taiwan, New Zealand, Spain
Ludwig Institute for Cancer Research
Cancer Research Institute, New York City; MedImmune LLC

Completed

A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

Melanoma | Sarcoma | Breast Cancer | Solid Tumor | Prostate Cancer | Bladder Cancer | Head and Neck Squamous Cell Carcinoma | Cutaneous T-Cell Lymphoma | Renal Cancer | Merkel Cell Carcinoma | Testicular Cancer

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer

Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell Carcinoma

United States
Alain Algazi
AstraZeneca; Incyte Corporation

Withdrawn

Durvalumab and Epacadostat for Treatment of Unresectable, Recurrent, or Metastatic Epstein-Barr Virus Positive Nasopharyngeal Cancer

Recurrent Nasopharyngeal Carcinoma | Metastatic Nasopharyngeal Carcinoma | Stage IV Nasopharyngeal Carcinoma | Epstein-Barr Virus Positive | Stage III Nasopharyngeal Carcinoma | Stage IVA Nasopharyngeal Carcinoma | Stage IVB Nasopharyngeal Carcinoma
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma (DOSa)

Recurrent Osteosarcoma | Refractory Osteosarcoma | Metastatic Osteosarcoma | Metastatic Angiosarcoma | Recurrent Dedifferentiated Liposarcoma | Metastatic Dedifferentiated Liposarcoma | Recurrent Angiosarcoma | Refractory Dedifferentiated Liposarcoma

United States
AstraZeneca

Recruiting

A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE (EMERALD-Y90)

Hepatocellular Carcinoma (HCC)

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); AstraZeneca

Active, not recruiting

Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer

Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Refractory Pancreatic Carcinoma | Stage II Pancreatic Cancer AJCC v8 | Stage III Pancreatic Cancer AJCC v8 | Stage IV Pancreatic Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC... and other conditions

United States
Academic and Community Cancer Research United
National Cancer Institute (NCI)

Recruiting

Regorafenib and Durvalumab for the Treatment of High-Risk Liver Cancer

Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IB Hepatocellular Carcinoma AJCC v8 | Stage II Hepatocellular Carcinoma AJCC v8

United States
The Netherlands Cancer Institute
AstraZeneca

Active, not recruiting

Improve Checkpoint-blockade Response in Advanced Urothelial Cancer (ICRA)

Urothelial Carcinoma

Netherlands
Sidney Kimmel Cancer Center at Thomas Jefferson...

Completed

Durvalumab With or Without Metformin in Treating Participants With Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma | Oropharyngeal Squamous Cell Carcinoma | Oral Cavity Squamous Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Acalabrutinib, Venetoclax and Durvalumab for the Treatment of Richter Transformation From Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma | Richter Syndrome

United States
University of Utah
National Cancer Institute (NCI)

Recruiting

Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in ARID1A Mutated Cancer Focus on Urothelial Carcinoma (RESOLVE)

Metastatic Urothelial Carcinoma | Locally Advanced Urothelial Carcinoma | Unresectable Urothelial Carcinoma | Infiltrating Urothelial Carcinoma, Sarcomatoid Variant

United States
M.D. Anderson Cancer Center

Recruiting

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer

Borderline Resectable Pancreatic Adenocarcinoma | Stage IA Pancreatic Cancer AJCC v8 | Stage IB Pancreatic Cancer AJCC v8 | Stage IIA Pancreatic Cancer AJCC v8 | Stage IIB Pancreatic Cancer AJCC v8 | Resectable Pancreatic Adenocarcinoma

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
OHSU Knight Cancer Institute
Oregon Health and Science University; Prospect Creek Foundation

Completed

Olaparib and Durvalumab in Treating Participants With Metastatic Triple Negative Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Prognostic Stage IV Breast Cancer AJCC v8 | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma

United States
IFOM ETS - The AIRC Institute of Molecular Oncology
AstraZeneca

Recruiting

Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-Paclitaxel (ATRiBRAVE)

Triple Negative Breast Cancer Metastatic

Italy
H. Lee Moffitt Cancer Center and Research Institute
AstraZeneca

Active, not recruiting

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

Small-cell Lung Cancer | Small Cell Lung Cancer Extensive Stage

United States
M.D. Anderson Cancer Center
AstraZeneca; Aravive Biologics Inc

Active, not recruiting

AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States
Emory University
National Cancer Institute (NCI)

Terminated

Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer

Lung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen

Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer

Castration-Resistant Prostate Carcinoma | Prostate Adenocarcinoma | Stage IV Prostate Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Stage IVA Prostate Cancer AJCC v8 | Stage IVB Prostate Cancer AJCC v8

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery

Hydronephrosis | Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant | Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage III Renal Pelvis Cancer AJCC v7 | Stage III Ureter Cancer AJCC v7 | Stage III Urethral Cancer AJCC v7 | Stage IV Renal Pelvis Cancer AJCC v7 | Stage IV... and other conditions

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab With or Without Tremelimumab in Treating Participants With Stage II-IVA Oropharyngeal Squamous Cell Cancer

Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7 | Stage II Oropharyngeal Squamous Cell Carcinoma AJCC v6 and v7

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer

Unresectable Hepatocellular Carcinoma | Stage III Hepatocellular Carcinoma AJCC v8 | Stage IIIA Hepatocellular Carcinoma AJCC v8 | Stage IV Hepatocellular Carcinoma AJCC v8 | Stage IVA Hepatocellular Carcinoma AJCC v8 | Stage IVB Hepatocellular Carcinoma AJCC v8 | BCLC Stage B Hepatocellular Carcinoma and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Platinum-Resistant Fallopian Tube Carcinoma | Platinum-Resistant Primary Peritoneal Carcinoma | Platinum-Resistant Ovarian Carcinoma | Refractory Ovarian Carcinoma | Refractory Fallopian Tube... and other conditions

United States

Search clinical trials for: Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations